Screener
King Pharmaceuticals KG % of Total
% of Total at other companies
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept kg:EquityMethodInvestmentsPercentOfTotal.
The source filing: King Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 8:49 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054606
| Line item | June 30, 2026 / Carrying Value | June 30, 2026 / % of Total | December 31, 2025 / Carrying Value | December 31, 2025 / % of Total |
|---|---|---|---|---|
| Real estate investments at equity method | $33,413 | 30.3% | $33,532 | 29.8% |
| Real estate investments at fair value option elected | 51,000 | 46.2% | 51,000 | 45.4% |
| Other equity method investments at fair value option elected | 25,870 | 23.5% | 27,911 | 24.8% |
| Total equity method investments with fair value option | 76,870 | 69.7% | 78,911 | 70.2% |
| Total equity method investments | $110,283 | 100.0% | $112,443 | 100.0% |
Item 1. Financial Statements
FAQ
- What is King Pharmaceuticals's % of total?
- King Pharmaceuticals (KG) reported % of total of $1 in Q2 2026.
- What does % of total mean?
- % of Total as reported by Kestrel Group Ltd.
Ask your AI about King Pharmaceuticals's % of total.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude